Hormone therapy in the WHI era

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 46, Issue 2, 2006, Pages 84-91

  Burger, Henry G ^a  

^a Jean Hailes Foundation for Women's Health   (Australia)

Author keywords

Breast cancer; Cardiovascular disease; Hormone therapy; Menopause; Osteoporosis; Venous thromboembolism

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; HORMONE; TIBOLONE;

BREAST CANCER; CARDIOVASCULAR FUNCTION; CHRONIC DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG FATALITY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FEMALE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LUNG EMBOLISM; MASTALGIA; MEDICAL PROFESSION; MENOPAUSAL SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS; STROKE; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

AGED; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FORECASTING; HUMANS; MENOPAUSE; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; THROMBOEMBOLISM; VICTORIA; WOMEN'S HEALTH;

EID: 33645353630     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2006.00533.x     Document Type: Review

References (37)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in health postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiologic studies of 52 705 women with breast cancer and 108 411 women without breast cancer (erratum in: Lancet 1997; 350: 1484). Lancet 1997; 350: 1047-1059.
3. Kuhl H. Is the elevated breast cancer risk observed in the WHI study an artefact? Climacteric 2004; 7: 319-323.
4. Burger H, Archer D, Barlow D, Birkhauser M et al. Expert workshop. Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2004; 7: 210-216.
5. Speroff L, Kenemans P, Burger HG. Practical guidelines for postmenopausal hormone therapy. Maturitas 2005; 16: 407.
6. Hays J, Ockene JK, Brunner RL et al. For the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-1854.
7. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.
8. Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: Did expectations shape experience? Ann Intern Med 2003; 139: 923-929.
9. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-1712.
10. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
11. Chlebowski RT, Hendrix SL, Langer RD et al. For the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003; 289: 3243-3253.
12. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review). Cochrane Database Syst Rev 2001; 1: CD002978.
13. Utian WH, Shoupe D, Bachman G, Pinkerton JV, Peckar JH. Relief of vasomotor systems and vaginal atrophy with lower doses of conjugated equine estrogen and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065-1079.
14. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996; 88: 587-592.
15. Utian WH, Burry KA, Archer DF et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients: The Esclim Study Group. Am J Obstet Gynecol 1999; 181: 71-79.
16. Peverill R. Hormone therapy and venous thromboembolism. In: Burger HG, Teede HJ (eds). Best Pract Res Clin Endocrinol Metab 2003; 17: 149-164.
17. Samsoie G. The menopause revisited. Int J Gynecol Obstet 1995; 51: 1-13.
18. Kenemans P, Speroff L. Tibolone: Clinical recommendations and practical guidelines: A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21-28.
19. Simon JA. Does osteopenia warrant treatment? Menopause 2005; 12: 639-648.
20. Seeman E, Eisman JA. Treatment of osteoporosis: Why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust 2004; 180: 298-303.
21. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-2676.
22. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women: A randomized controlled trial. JAMA 2003; 290: 1042-1048.
23. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822.
24. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer JA. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941.
25. Williams JK, Anthony MS, HonoréEK et al. Regression of atherosclerosis in female monkeys. Arterioscler Thomb Vasc Biol 1995; 15: 827-836.
26. Manson JE, Hsia J, Johnson KC et al. For the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart diseae. N Engl J Med 2003; 349: 523-534.
27. Naftolin F, Taylor HS, Karas R et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004; 81: 1498-1501.
28. Phillips LS, Langer RD. Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83: 558-566.
29. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy early postmenopausal women. Arch Intern Med 2004; 164: 482-484.
30. Shumaker SA, Legault C, Thal L et al. For the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003; 289: 2651-2662.
31. Zandi PP, Carlson MC, Plassman BL et al. For the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 2002; 288: 2123-2129.
32. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al. For the Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 250: 991-1004.
33. Newton KM, LaCroix AZ, Heckbert SR et al. Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes. Diabetes Care 2003; 26: 2810-2816.
34. Ferrara A, Quesenberry CP, Karter A et al. Northern California Kaiser Permanente Diabetes Registry. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: The Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation 2003; 107: 43-48.
35. Kanaya AM, Herrington D, Vittinghoff E et al. Heart and Estrogen/ progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 7: 1-9.
36. Margolis KL, Bonds DE, Rodabough RJ et al. For the Women's Health Initiative Investigators: Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the Women's Health Initiative Hormone Trial. Diabetologia 2004; 47: 1175 -1187.
37. Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004; 7: 333-337.